LY4101174, a novel nectin-4-targeting ADC in solid tumors [Video]

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on a Phase I trial (NCT06238479) of LY4101174 (ETx-22), a next-generation antibody-drug conjugate (ADC) targeting nectin-4, for advanced solid tumors expressing nectin-4. The study follows a dose escalation and expansion design to establish the recommended Phase II dose, assess safety, pharmacokinetics, immunogenicity, and antitumor activity, correlating biomarkers with clinical outcomes. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.